Ability Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ibrilatazar (ABTL0812) / Ability Pharma
NCT03362892: A Phase I/II Study of ABTL0812 (Pancreatic)

Not yet recruiting
1/2
46
NA
sodium 2-hydroxylinoleate
Ability Pharmaceuticals SL
Pancreatic Cancer
07/19
07/21
2020-002791-13: A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Not yet recruiting
1/2
144
Europe
ABTL0812, ABTL0812, Oral solution
Ability Pharmaceuticals, SL, Ability Pharmaceuticals, SL
Metastatic pancreatic cancer, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
NCT03417921: A Study of ABTL0812 in Pancreatic Cancer

Suspended
1/2
60
Europe
ABTL0812, Gemcitabine and nab-paclitaxel
Ability Pharmaceuticals SL, The Cleveland Clinic
Pancreatic Cancer
04/23
12/24
PanC-ASAP, NCT04431258: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Completed
1/2
150
Europe, US, RoW
ABTL0812, Folfirinox, Chemotherapy, Placebo
Ability Pharmaceuticals SL
Pancreatic Cancer
01/24
01/24

Download Options